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Essentials 
• Platelets in trauma-induced coagulopathy (TIC) are impaired, but the mechanism is not known. • We performed comprehensive longitudinal platelet function testing in trauma patient samples. • Platelets in TIC are widely impaired early after injury, but platelet activatability is intact. • This suggests a mechanism of transient platelet cytoskeletal/integrin dysfunction during TIC.  
Abstract 
Background. Trauma-induced coagulopathy (TIC) is a common and deadly bleeding disorder. Platelet 
dysfunction is present during TIC, but its mechanisms remain unclear. Platelets are currently thought to 
become “exhausted”, a state in which they have released their granule contents and can no longer 
aggregate or contract. Methods. This prospective observational cohort study tested the hypothesis that 
platelet exhaustion is present during TIC and characterized the early time course of platelet dysfunction. 
Blood was collected from 95 adult trauma patients at a Level I trauma center at time of Emergency 
Department arrival and several time points over 72 hours. Platelet activation state and function were 
characterized using CD62P (P-selectin) and PAC-1 surface membrane staining, PFA-100, aggregometry, 
viscoelastic platelet mapping, and, to test for exhaustion, their ability to express CD62P after ex vivo 
adenosine diphosphate (ADP) agonism. Platelet function was compared between patients with and 
without TIC, defined by prothrombin time ≥ 18 seconds. Results. Platelets in TIC showed no initial 
increase in their level of surface activation markers or impairment of their capacity to express CD62P in 
response to ADP stimulation. However, TIC platelets were impaired in nearly all functional assays, 
spanning adhesion, aggregation, and contraction. These effects largely remained after controlling for 
platelet count and fibrinogen concentration and resolved after 8 hours. Conclusion. TIC platelets exhibit 
early impairment of adhesion, aggregation, and contraction with retained alpha granule secretion 
ability, suggesting a specific mechanism of cytoskeletal or integrin dysfunction that is not a result of 
more general platelet exhaustion. 
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Introduction 
Trauma is a leading cause of death and disability, both in the United States and worldwide.(1) Bleeding 
is the second leading cause of death and the leading cause of preventable death in injured patients.(2, 3) 
Trauma-induced coagulopathy (TIC) is a common and deadly complication of injury, occurring in 25-35% 
of severely injured patients and associated with a 3- to 4-fold increase in mortality.(4, 5) TIC manifests as 
a complex, multifactorial derangement of hemostasis. 
The importance of platelets in hemostasis is difficult to overstate. They serve as the primary substrate 
for clot initiation, the staging ground for the coagulation cascade and thrombin generation, and a key 
contributor to mechanical clot strength. In fact, platelet-mediated clot contraction contributes over 80% 
of overall clot stiffness and is the primary regulator of clot lysis after injury.(6-9) 
The platelet lesion in TIC is complex and poorly understood. Platelet adhesion, measured using the PFA-
100, has trended towards shorter aperture closure times after trauma, suggesting enhanced platelet 
adhesive function.(10) However, decreased platelet aggregation in response to common agonists is 
common, present in as many as 45% of patients with major trauma, and is associated with a remarkable 
10-fold higher early mortality.(11-13) Further examination of platelet-mediated clot contraction using 
thrombelastography platelet mapping has also detected significantly decreased contractile 
responsiveness to ADP, arachidonic, and, to a lesser extent, thrombin receptor stimulation in trauma 
patients.(14) 
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Despite this appearance of platelet hypofunction, platelets tend to appear activated after injury, as 
determined by membrane markers of platelet activation. Trauma patients tend to have either normal or 
increased levels of platelet-derived microparticles and increased membrane markers of platelet 
activation (CD62P and PAC-1).(10, 13) These increased levels of activation markers combined with 
decreased function has spawned a theory in which platelets quickly become “exhausted” after major 
trauma, meaning they have become activated and released the contents of their granules and 
consequently lose their ability to contribute mechanically to clot formation by their aggregation and 
contraction. Platelet exhaustion was originally described in a small group of patients with a 
heterogeneous collection of disease processes: renal allograft rejection, hemolytic uremic syndrome or 
thrombotic thrombocytopenic purpura, disseminated intravascular coagulation due to incompatible 
transfusion, and systemic lupus erythematosus.(15) They collectively exhibited a particular platelet 
phenotype of decreased aggregation, reduced adenine nucleotide and serotonin content, and bleeding 
time prolonged beyond what the platelet count would predict. Supporting this theory for trauma, 
platelet CD62P (P-selectin) expression, an indicator of alpha granule release, after ex vivo ADP 
stimulation has been found to be modestly decreased in platelets from trauma patients.(13)  
We previously demonstrated that significant platelet dysfunction contributed to distinct hemostatic 
responses in Emergency Department patients when identified using hierarchical clustering analysis.(16) 
Platelet-induced clot contraction was also found to be strongly associated with thromboelastography 
(TEG) clot formation when measured in the same Emergency Department cohort(7), suggesting that 
platelet dysfunction was an important component of TIC in this cohort of trauma patients. In the present 
study, we look more specifically at platelet function in this cohort to elucidate the mechanism of the 
noted platelet dysfunction. Because trauma patients’ coagulability status can be dynamic over the early 
days after injury, we also examined changes in platelet function over the first 3 days of hospital 
admission. We hypothesized that platelets from those subjects meeting criteria for TIC would display 
platelet exhaustion, identified by increased surface membrane markers of activation (CD62P and PAC-1), 
decreased secretion response to further ex vivo agonism, and decreased adhesion, aggregation, and clot 
contraction. Our secondary hypothesis was that this phenotype would gradually normalize over the first 
three days, with any differences becoming non-significant at 72 hours. To test these hypotheses, we 
prospectively measured platelet phenotypes in this cohort at Emergency Department arrival and serially 
over the first 3 days of hospital admission. 
 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
Methods 
Study Design and Patient Population 
This was a prospective cohort study of trauma patients presenting to an urban Level I trauma center, 
from which some of the non-platelet-specific findings have been previously reported.(7) In brief, trauma 
patients were identified from trauma team activations, which are triggered by criteria meant to capture 
patients with serious injury. Subjects were screened, and consent for study participation was obtained 
from either the patient or a legally authorized representative. Blood was collected into standard 
vacutainers at the time of ED arrival and before the patients received any blood products. Additional 
blood samples were collected at 8, 24, 48, and 72 hours after arrival. To minimize confounding 
influences of blood transfusion, minor injury, or survival bias, subjects were excluded if they received 
any blood products prior to study sample blood draw, were not expected to survive for 3 days after 
injury, or were minimally injured and either did not require admission or were expected to be 
discharged from the hospital before 3 days of hospitalization. Vital signs, injury profiles, and outcomes 
were collected from the medical record, and the injury severity score (ISS) and sequential organ failure 
assessment (SOFA) were calculated for each patient. The study was approved by the Virginia 
Commonwealth University institutional human subjects review board. 
Assays 
All samples were processed in the Virginia Commonwealth University coagulation advancement lab, 
Virginia Commonwealth University School of Pharmacy. All measurements were carried out within 2 
hours of sample collection, as previously described.(7) Briefly, platelet adhesion and aggregation in 
response to collagen/ADP and collagen/epinephrine stimulation were measured by the PFA-100 (Dade 
International, Deerfield, IL). Isolated platelet aggregation in response to ADP (10 µM) and collagen (2 
µg/mL) was measured using a whole blood impedance aggregometer (Chronolog, Havertown, PA). 
Platelet contractile force (PCF) and clot elastic modulus (CEM) were measured in re-calcified whole 
blood using the Hemostasis Analysis System (HAS) (Hemodyne Inc., Richmond, VA). Viscoelastic clot 
formation was measured in whole blood using TEG (TEG 5000, Haemonetics Corp., Braintree, MA) using 
recalcification (10mM Ca
2+
) and kaolin stimulation, as well as standard TEG platelet mapping (TEG-PM). 
Platelet flow cytometry was performed using an Accuri™ C6 flow cytometer (BD Biosciences, San Jose, 
CA, USA) on whole blood samples stained with antibodies specific to the activated form of α IIbβ3 
(monoclonal antibody PAC-1 conjugated with fluorescein isothiocyanate conjugate [FITC], BD 
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Biosciences, San Jose, CA, USA) and CD62P (mouse anti-human CD62P monoclonal antibody conjugated 
with phycoerythrin [PE], BD Pharmingen, Franklin Lakes, NJ).  CD62P staining was also performed on 
whole blood samples after ex vivo incubation with ADP (5μM) for 2 minutes to detect platelet 
responsiveness to further stimulation. The Accuri C6 fluidics was set to the medium flow rate and a 
forward scatter threshold of 30,000. Twenty thousand events were collected into a pre-set platelet gate 
using standard methods including anti-CD41a conjugated with PE-Cy5 (mouse anti-human, BD 
Pharmingen, Franklin Lakes, NJ) as a platelet marker.  Collected data were analyzed using the FlowJo 
software package version 7.6.5 (FlowJo, Ashland, OR). 
Definitions and Statistical Approach 
In the primary analysis, patients were divided into two groups according to the presence or absence of 
TIC at Emergency Department arrival, which was originally defined as PT ≥ 18.(17) This definition was 
chosen for consistency with previous literature and because this plasma-based definition is independent 
of any specific type of platelet dysfunction. We have used a similar definition in previous studies, thus 
facilitating comparisons.(7) Demographics and test results were compared using the chi square test for 
dichotomous variables, Student’s t-test for normally distributed variables, and Mann-Whitney U test for 
non-normally distributed variables at each individual time point. 
To test whether any platelet function defects were independent of platelet count and fibrinogen 
concentration, we fit the data to a multivariate linear regression model. The model included as 
independent variables platelet count, fibrinogen concentration, and a dichotomous variable 
representing the presence or absence of TIC and as the dependent variable the numerical assay result of 
interest. The Wald test was performed on the TIC term to determine statistical significance in predicting 
an independent difference in assay result. 
A secondary analysis was also performed to examine the time course of platelet function in TIC. This 
analysis included only the patients with a complete set of data for the duration of the 72-hour study. 
Patients were characterized as either having or not having TIC according to their results at hour 0. To 
determine the overall and group-specific effects of time, a generalized estimating equation (GEE) was fit 
to the data with terms for time, the presence of TIC, and the interaction between time and the presence 
of TIC. Robust standard errors were used to account for heteroskedasticity. Lab values at individual time 
points were compared by Wilcoxon rank-sum test. 
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Several lab values were censored beyond certain detection limits. These include PT > 70 sec, PTT > 120 
sec, fibrinogen < 100 mg/dL, and PFA-100 collagen/ADP and collagen/epinephrine closure times > 300 
sec. 
For all tests, a p-value less than 0.05 was considered significant. All statistics were run using Stata SE 
13.1 (StataCorp, College Station, TX). 
 
Results 
One hundred seventy three trauma patients were screened for inclusion, of which 95 met inclusion 
criteria and were included in the primary analysis with 15 exhibiting TIC, as previously described.(7) 
Descriptive characteristics are included in Table 1. In brief, at the time of ED arrival TIC patients had 
lower systolic and diastolic blood pressure, higher heart rate, higher Injury Severity Score, lower 
Glasgow Coma Score, higher base deficit, and lower hemoglobin and hematocrit. The coagulation data 
that are not platelet-specific were reported previously.(7) 
Platelet test results at the time of ED arrival are summarized in Table 2. TIC patients showed longer PFA-
100 closure times in response to collagen and epinephrine, though not in response to collagen and ADP. 
They also showed impaired aggregation in response to both ADP and collagen. Few platelets stained 
positive for PAC-1 or CD62P at ED arrival, and there were no differences between groups. Platelets from 
both groups also responded briskly to ex vivo ADP stimulation with similarly increased expression of 
CD62P (Figure 1). 
As previously described, TIC patients had decreased platelet counts and fibrinogen concentrations.(7) 
After controlling for these variables, the effect of TIC on PFA-100 closure time in response to 
collagen/epinephrine remained significant (p=0.010) and in response to PFA-100 collagen/ADP remained 
non-significant (p=0.362). The association between TIC and impaired platelet aggregation in response to 
both ADP and collagen also remained significant (p=0.007 and 0.010, respectively). The associations 
between TIC, TEG maximum amplitude (MA), and percent lysis at 30 minutes after onset (LY30) became 
non-significant after adjusting for platelet count and fibrinogen concentration (p=0.149 and 0.133, 
respectively). The association of TIC with PCF was also no longer significant (p=0.841). The effect of TIC 
on TEG-PM in response to ADP and AA remained non-significant (p=0.997 and 0.070, respectively). 
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Fifty subjects had a complete data set and were included in the longitudinal analysis. Their descriptive 
characteristics are summarized in Table 3, and their platelet function test results are summarized in 
Table 4 (GEE analysis) and Table 5 (individual time point data). Both aggregation and TEG MA were 
decreased in the TIC group across all time points. The platelet count decreased in both groups over time 
but more quickly in the TIC group. The fibrinogen concentration was decreased initially in the TIC group, 
but increased over time and more quickly for the TIC group. Remarkably, many of the early platelet 
defects seen in the TIC group at ED arrival were no longer significant by Hour 8. This response was seen 
in aggregation in responses to both ADP and collagen, TEG MA, and PCF. There were also general pro-
hemostatic trends with time in many assays, including ADP aggregation, TEG MA, PCF, CEM, and TEG-PM 
ADP and AA inhibition. These values sometimes reached and exceeded the pro-hemostatic limit of the 
reference range. Collagen aggregation improved with time only in the TIC group. One notable exception 
to this trend is PFA-100, which prolonged with time in both groups. Individual time point comparisons 
revealed decreased platelet adhesion in the TIC group at early and late time points, though they 
remained mostly within the reference range. CD62P expression was lower across time in the TIC group, 
though no individual time point was different enough to reach significance. There were no differences in 
PAC-1 expression or ADP-induced CD62P expression across time or at any single time point. 
 
Discussion 
Our results identify a platelet dysfunction in TIC that primarily involves aggregation, manifests during 
the critical early hours after injury, and does not include alpha granule secretory dysfunction. This 
suggests a central mechanism of specific cytoskeletal or integrin dysfunction underlying the TIC platelet 
phenotype and does not support generalized platelet exhaustion as previously described. 
We found no difference in levels of platelet activation state on arrival to the ED, as evidenced by the 
percentage of platelets that bound the PAC-1 antibody (specific for the activated form of α IIbβ3) or the 
anti-CD62P antibody (specific for exocytosed alpha granule membrane). Furthermore, TIC platelets were 
not different in their ability to release granules upon ex vivo activation by ADP stimulation. Prior studies 
have shown mixed results in this area. One found a modest but statistically significant decrease in 
inducible CD62P expression in trauma patients(13), and another found that dense granule content was 
maintained in trauma patient platelets.(18) The current study is larger and more comprehensive than 
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previous work on this subject, and it suggests that platelets remain activatable and are thus not fully 
exhausted during TIC. 
We also found that platelet dysfunction that was relatively common and phenotypically consistent with 
several prior studies. Most consistent was the loss of adhesive and aggregation function during TIC. 
Previous work has found similar functional phenotypes where platelet aggregation, measured by 
impedance aggregometry, was decreased and its decrease was significantly associated with increased 
mortality.(11-13) Of note, each of these prior studies showed decreased responses to different agonists, 
which could suggest that the impairment is occurring in a downstream intracellular activation pathway 
common to all agonists. Our study took this analysis one step further and found that these impairments 
remained after statistically controlling for fibrinogen concentration and platelet count as possible 
confounders. 
The presence of both normal secretory activity and impaired aggregation during TIC in this study 
suggests that platelet dysfunction in TIC is more likely to arise either from an abnormal intracellular 
signaling pathway common to numerous platelet stimuli that is downstream from granule secretion or 
from integrin dysfunction (Figure 2). In fact, the TIC platelets in this study are phenotypically similar to 
the α IIbβ3 dysfunction seen in Glanzmann thrombasthenia (GT). The defining phenotypic characteristic 
of GT is globally impaired platelet aggregation, which was present in our TIC population.(19) Viscoelastic 
thrombus strength, elastic modulus, and contractile force are also all decreased in GT, all of which was 
seen in the TIC group.(20, 21) Impaired α IIbβ3 adhesive function also results in decreased platelet 
contraction.(22) GT patients typically exhibit prolonged PFA-100 closure times,(23) which was partially 
seen in TIC patients. GPIb and α IIbβ3 receptors are also known to be susceptible to cleavage and 
inactivation by plasmin proteolytic activity, which is increased during TIC.
(24-26)
 Increased plasmin activity 
in this cohort is also supported by our previous work showing increased fibrinolysis during TIC in this 
cohort.
7
 Therefore, derangement of α IIbβ3
Another important finding of our study is that the duration of platelet impairment was short-lived. Most 
assays trended toward becoming pro-hemostatic over time, sometimes exceeding the limit of the 
reference range. The deficiencies seen at the time of ED arrival were mostly resolved by the next time 
point 8 hours later (ADP and collagen aggregation, TEG MA, and PCF). This dysfunction occurs in the 
critical early hours after injury, during which most mortality attributable to hemorrhage after trauma 
takes place.(27) The recovery time is not due to the loss of data from non-survivors in later time points, 
 function during TIC could result from its abnormal 
intracellular activation, cleavage of receptors, or binding to hypofunctional ligands. 
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as all patients who did not survive the full 72 hours were excluded from this analysis. It is possible that 
the rapid recovery is due to transfusion of healthy platelets, because there was a significantly higher 
volume of platelets transfused to the TIC group. However, this is made less likely by the fact that the 
actual amounts transfused to both groups were quite small at 8 hours (medians of 0 and 20 mL of 
pooled platelets in the non-TIC and TIC groups, respectively). It is also somewhat unclear whether the 
population included in the longitudinal analysis accurately represent the larger population included in 
the primary analysis. While the defects seen in the TIC group in the larger primary analysis were 
consistently reproduced in the smaller longitudinal population at Hour 0 (decreased ADP aggregation, 
collagen aggregation, and PCF), one test was not (prolonged collagen/epinephrine PFA-100 closure, 
which lost significance at p=0.090). It is unclear whether this lost significance is from a loss of power in 
the smaller longitudinal population (50 vs. 95 patients in the primary analysis) or selection bias towards 
healthier patients having complete longitudinal data, but both effects may have certainly contributed. 
There are several longitudinal studies published on TIC, and only a handful on platelet dysfunction after 
trauma. One study showed prolongation of PFA-100 closure times through the entire 72-hour follow-up 
period(10), which we have replicated, and another showed a decline in aggregation function that 
occurred early and persisted throughout the 24-hour follow-up period(28). There has been a broad 
range of reported durations of TIC, ranging from 6 hours to 5 days after injury, and the duration appears 
to be highly dependent on the resuscitation methods employed.(29, 30) The reason for our discrepant 
results could be that the resuscitation strategy employed at this trauma center rapidly corrects 
coagulopathy, or that the current cohort was less injured than others (mean Injury Severity Score of 
20).(7) The persistence of PFA-100 abnormalities in TIC suggests a lasting defect specific to the adhesion 
pathway that requires further investigation. 
Our study has several limitations. First, it is an observational study that should be generalized with 
caution. Second, our longitudinal analysis cohort excluded patients who were not expected to survive 72 
hours. This removed the effect of survival bias on our data. However, patients who die in the early 
period after injury also tend to be the ones who develop the most severe TIC. Since the longitudinal 
cohort survived for at least 72 hours after injury, they were capable of achieving hemostasis, suggesting 
that platelets remained capable of making important contributions to hemostasis in this less-severe TIC 
phenotype. Third, our study sample included only a relatively small number of patients with TIC (n=15). 
Fourth, as with any similarly designed study, the analysis of circulating platelets is subject to some 
selection bias, as these platelets likely do not accurately represent those that are participating in 
thrombus formation. As it is difficult to sample platelets actively participating in thrombus formation, 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
this bias was unavoidable within the constraints of our study design, but it should be remembered when 
interpreting our findings. Fifth, our study was not designed or powered to examine any phenotypically 
distinct subtypes of TIC. The coagulopathy associated with isolated brain injury is perhaps the best-
described example of this. A set of simple regression analyses (not shown) found no significant 
correlation between TBI severity and the abnormalities seen in PFA-100 or aggregometry, but this could 
be due to a lack of power for this exploratory analysis. Finally, several variables that would have been 
helpful to further define the platelet abnormality observed (e.g., VWF concentration, VWF multimer 
profile, PAC-1 and anti-CD62P ligand density) were not collected. Future studies should investigate in 
greater detail the underlying cause of functional platelet impairment after trauma. A more focused and 
detailed approach to the specific lesion, focusing on integrin expression and cellular function taking 
place downstream from initial activation events, is needed to improve future clinical management of 
this disorder. 
In conclusion, our data indicate that circulating TIC platelets are dysfunctional primarily in their ability to 
mechanically aggregate and contract but maintain normal alpha granule secretory function. Their 
aggregatory and contractile dysfunction resolves within 8 hours in surviving trauma patients. Platelet 
integrin dysfunction or inhibition is a clear target for further investigation into the mechanism of platelet 
dysfunction during TIC. 
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Tables 
 
Table 1. Descriptive characteristics of included patients, stratified by the presence of TIC.(7) Vital signs 
and laboratory values are at time of ED arrival. Data are presented as median (interquartile range). P-
values obtained by Wilcoxon rank-sum test. 
 All Included 
Patients (n=95) 
No TIC (n=80) TIC (n=15) P 
Demographics/Vital Signs     
Age, years 33 (24-50) 33 (24-52) 36 (22-45) 0.353 
Heart Rate, beats per min 98 (78-115) 93 (78-111) 110 (101-136) 0.006 
Systolic Blood Pressure, mmHg 126 (112-149) 129 (116-152) 112 (89-127) 0.010 
Diastolic Blood Pressure, mmHg 80 (67-90) 80 (68-91) 71 (53-81) 0.025 
Respiratory Rate, breaths per min 18 (15-22) 18 (15-21) 20 (17-26) 0.133 
Oxygen Saturation, % 99 (97-100) 99 (97-100) 98 (95-100) 0.522 
Temperature, °C 36.4 (36.1-36.9) 36.5 (36.1-36.9) 36.3 (35.7-36.5) 0.182 
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Injury Severity Score 17 (10-27) 15 (9-25) 30 (21-43) <0.001 
Glasgow Coma Score 15 (6-15) 15 (9-15) 9 (3-15) 0.048 
Laboratory Values     
[Lactate], mmol/L 3.6 (2.4-5.2) 3.4 (2.4-5.0) 4.5 (3.1-5.5) 0.088 
Base Deficit, mEq/L 2.1 (-0.4-5.4) 1.6 (-0.8-4.9) 5.4 (2.1-14.5) 0.001 
Hemoglobin, g/dL 12.9 (11.4-14.0) 13.3 (11.8-14.5) 10.5 (8.6-11.9) <0.001 
Hematocrit, % 37.0 (32.7-41.9) 37.9 (33.7-43.1) 32.4 (29.4-36.4) <0.001 
Platelet Count, x10
9
229 (183-273) /L 231 (187-279) 211 (156-250) 0.162 
PT, sec 14.7 (13.5-16.1) 14.4 (13.4-15.5) 19.5 (18.5-21.2) <0.001 
aPTT, sec 32.2 (29.3-35.7) 31.3 (28.8-34.2) 39.7 (34.4-49.4) <0.001 
Fluid Resuscitation, mL     
Total Crystalloid at Hour 0 1300 (400-2000) 1000 (300-2000) 2000 (1400-2600) 0.037 
Total Blood Products at Hour 0 0 (0-0) 0 (0-0) 0 (0-0) 0.212 
 
Table 2. Platelet-specific data for all trauma patients at hour 0, stratified by the presence of TIC. Data 
are presented as median (interquartile range). P-values obtained by Wilcoxon rank-sum test. REF, 
reference range; AUC, area under the curve. 
Lab Value No TIC (n=80) TIC (n=15) P 
Platelet count, x10
9
231 (187-279) /L (REF 150-450) 211 (156-250) 0.162 
PFA-100 collagen/epinephrine closure time, sec 
(REF <180) 
97 (84-126) 155 (119-300) 0.002 
PFA-100 collagen/ADP closure time, sec (REF <120) 64 (54-81) 70 (49-129) 0.613 
Platelet ADP aggregation, ohms (REF 6-24) 11.0 (8.5-13.0) 6.0 (3.5-8.5) 0.001 
Platelet collagen aggregation, ohms (REF 14-28) 14.5 (12.0-18.0) 12.0 (6.5-13.5) 0.002 
Platelet Contractile Force, Kdynes 8.0 (6.6-9.4) 6.0 (5.0-8.7) 0.029 
TEG-PM ADP inhibition, % 78.7 (57.8-97.0) 96.1 (65.2-97.3) 0.292 
TEG-PM AA inhibition, % 38.9 (19.6-65.8) 35.1 (13.7-52.0) 0.356 
Percent PAC-1-positive 6.0 (1.8-12.6) 3.5 (0.5-10.2) 0.265 
Percent CD62P-positive 3.0 (1.4-7.8) 2.6 (0.8-5.7) 0.268 
Percent that became CD62P-positive after ADP 
stimulation 
70.1 (57.5-76.8) 72.5 (63.2-77.2) 0.914 
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Table 3. Descriptive characteristics of the 50 patients included in the longitudinal data analysis. Data 
are presented as median (interquartile range). P-values obtained by Wilcoxon rank-sum test. 
 All Included 
Patients (n=50) 
No TIC (n=38) TIC (n=12) P 
Demographics/Vital Signs     
Age, years 37 (24-53) 44 (25-54) 27.5 (23.5-42.5) 0.149 
Heart Rate, beats per min 100 (84-116) 98 (80-108) 117 (104-135) 0.011 
Systolic Blood Pressure, mmHg 127.5 (112-151) 132 (118-153) 112 (94-116) 0.005 
Diastolic Blood Pressure, mmHg 76.5 (61-92) 81 (64-96) 61 (49.5-77) 0.006 
Respiratory Rate, breaths per min 18.5 (15-24) 18 (14-24) 20 (17.5-25) 0.487 
Oxygen Saturation, % 99 (97-100) 99 (97-100) 99 (96-100) 0.812 
Temperature, °C 36.3 (35.9-36.7) 36.3 (36.0-36.8) 36.0 (35.5-36.5) 0.260 
Injury Severity Score 22 (14-30) 19 (13-29) 28.5 (21-42) 0.012 
Glasgow Coma Score 13.5 (3-15) 14.5 (3-15) 7 (3-14) 0.144 
Laboratory Values     
[Lactate], mmol/L 4.4 (2.8-5.2) 3.8 (2.7-4.9) 5.2 (4.5-11.2) 0.007 
Base Deficit, mEq/L 3.1 (1.0-6.5) 2.2 (0.7-4.8) 7.8 (3.9-13.6) <0.001 
Hemoglobin, g/dL 13.3 (11.8-14.4) 13.9 (12.5-14.9) 11.0 (10.2-13.0) <0.001 
Hematocrit, % 36.5 (32.5-41.0) 38.6 (35.3-43.6) 32.3 (30.4-35.9) 0.004 
Platelet Count, x10
9
236 (177-279) /L 243 (179-284) 217 (151-265) 0.156 
PT, sec 15.1 (14.0-17.7) 14.7 (13.7-15.3) 20.2 (19.3-21.2) <0.001 
aPTT, sec 33.5 (29.5-38.2) 32.3 (29.0-35.7) 39.0 (32.6-46.1) 0.007 
Crystalloid Fluid Resuscitation, mL     
Total Crystalloid Given at Hour 0 1500 (500-2000) 1200 (350-2000) 2100 (2000-3000) 0.003 
Total Crystalloid Given at Hour 8 550 (0-2700) 547 (0-2660) 1668 (253-4090) 0.520 
Blood Products at Hour 8, mL     
Total Blood Products 0 (0-620) 0 (0-310) 1400 (310-2555) <0.001 
Packed Red Blood Cells 0 (0-620) 0 (0-310) 930 (310-1550) <0.001 
Fresh Frozen Plasma 0 (0-0) 0 (0-0) 225 (0-788) <0.001 
Pooled Platelets 0 (0-0) 0 (0-0) 20 (0-200) <0.001 
Apheresis Platelets 0 (0-0) 0 (0-0) 0 (0-0) 0.011 
Cryoprecipitate 0 (0-0) 0 (0-0) 20 (0-200) 0.015 
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Table 4. Generalized estimating equation results for longitudinal data. The coefficient represents the 
change in the lab value associated with either the presence of TIC (TIC), a 1-unit increase in time (Time), 
or a 1-unit increase in time in the presence of TIC (TIC*Time). GEE, generalized estimating equation; CI, 
confidence interval. 
Lab Value GEE Coefficient 
[95% CI] 
P 
Platelet count, x10
9
 /L:  
TIC -28.2 [-63.8, 7.3] 0.119 
Time -0.64 [-0.92, -0.36] <0.001 
TIC*Time -0.52 [-1.03, -0.02] 0.042 
PT, sec:   
TIC 4.0 [3.3, 4.7] <0.001 
Time 0.01 [0, 0.02] 0.156 
TIC*Time -0.04 [-0.07, -0.02] 0.001 
aPTT, sec:   
TIC 2.0 [-3.3, 7.3] 0.455 
Time 0.13 [0.06, 0.20] <0.001 
TIC*Time 0.04 [-0.13, 0.21] 0.623 
Fibrinogen concentration, mg/dL:   
TIC -93.0 [-139.8, -46.2] <0.001 
Time 6.62 [5.66, 7.59] <0.001 
TIC*Time 1.97 [0.36, 3.58] 0.016 
PFA-100 collagen/epinephrine closure time, sec:   
TIC 11.9 [-27.3, 51.0] 0.553 
Time 0.07 [-0.38, 0.53] 0.747 
TIC*Time 0.31 [-0.50, 1.12] 0.459 
PFA-100 collagen/ADP closure time, sec:   
TIC 14.5 [-16.5, 45.5] 0.360 
Time 0.56 [0.18, 0.95] 0.004 
TIC*Time 0.95 [-0.12, 2.02] 0.083 
Platelet ADP aggregation, ohms:   
TIC -2.4 [-4.3, -0.5] 0.014 
Time 0.02 [0, 0.04] 0.014 
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TIC*Time 0.04 [-0.01, 0.09] 0.103 
Platelet collagen aggregation, ohms:   
TIC -2.8 [-4.6, -1.1] 0.002 
Time 0.01 [-0.02, 0.03] 0.619 
TIC*Time 0.05 [0, 0.10] 0.036 
HAS platelet contractile force, kdynes:   
TIC -1.2 [-2.4, 0] 0.053 
Time 0.04 [0.02, 0.07] 0.001 
TIC*Time 0.03 [-0.02, 0.08] 0.277 
HAS clot elastic modulus, kdynes/cm
2
 :  
TIC -2.6 [-7.0, 1.8] 0.250 
Time 0.17 [0.07, 0.27] 0.001 
TIC*Time -0.01 [-0.19, 0.17] 0.926 
TEG MA, mm:   
TIC -3.5 [-6.7, -0.4] 0.028 
Time 0.11 [0.08, 0.15] <0.001 
TIC*Time 0.05 [-0.02, 0.12] 0.145 
TEG LY30, %:   
TIC 2.7 [-0.4, 5.8] 0.087 
Time 0.02 [0, 0.04] 0.113 
TIC*Time -0.06 [-0.13, 0] 0.051 
TEG-PM ADP inhibition, %:   
TIC -1.7 [-16.8, 13.4] 0.822 
Time -0.43 [-0.56, -0.30] <0.001 
TIC*Time -0.02 [-0.28, 0.25] 0.905 
TEG-PM AA inhibition, %:   
TIC -9.3 [-22.8, 4.2] 0.177 
Time -0.23 [-0.39, -0.08] 0.003 
TIC*Time -0.06 [-0.42, 0.31] 0.768 
Percent PAC-1-positive:   
TIC -6.7 [-13.7, 0.2] 0.058 
Time 0.05 [0.03, 0.13] 0.261 
TIC*Time 0.11 [-0.06, 0.29] 0.207 
Percent CD62P-positive:   
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TIC -3.1 [-5.7, -0.5] 0.019 
Time -0.02 [-0.05, 0.02] 0.305 
TIC*Time 0.02 [-0.02, 0.05] 0.397 
Percent that became CD62P-positive after ADP 
stimulation: 
  
TIC -5.4 [-14.8, 4.0] 0.256 
Time 0 [-0.06, 0.06] 0.940 
TIC*Time 0.08 [-0.04, 0.21] 0.180 
 
 
 
Table 5. Longitudinal laboratory value data for subset of patients with complete longitudinal data, 
stratified by the presence of TIC at hour 0. Data are presented as median (interquartile range). P-values 
obtained by Wilcoxon rank-sum test. 
Lab Value Non-TIC (n=38) TIC (n=12) P 
Platelet count, x10
9
 /L (REF 150-450):   
Hour 0 243 (179-284) 217 (151-265) 0.156 
Hour 8 208 (174-256) 181 (115-248) 0.251 
Hour 24 190 (155-240) 142 (115-185) 0.044 
Hour 48 176 (139-231) 132 (107-145) 0.005 
Hour 72 186 (147-237) 122 (109-151) 0.001 
PT, sec (REF 11-15):    
Hour 0 14.7 (13.7-15.3) 20.2 (19.3-21.2) <0.001 
Hour 8 14.4 (13.8-15.6) 16.7 (16.0-18.1) <0.001 
Hour 24 15.2 (14.0-17.2) 17.8 (17.2-18.6) <0.001 
Hour 48 15.6 (14.2-16.9) 17.2 (15.2-17.9) 0.071 
Hour 72 14.8 (13.8-16.6) 16.2 (15.1-17.6) 0.030 
aPTT, sec (REF 25-40):    
Hour 0 32.3 (29.0-35.7) 39.0 (32.6-46.1) 0.007 
Hour 8 33.9 (30.4-36.8) 34.6 (32.3-39.4) 0.570 
Hour 24 39.9 (34.8-44.7) 41.1 (38.1-47.2) 0.394 
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Hour 48 41.1 (35.9-47.0) 42.1 (36.6-52.3) 0.733 
Hour 72 39.7 (36.4-44.6) 45.7 (39.9-55.8) 0.058 
Fibrinogen concentration, mg/dL (REF 250-400):    
Hour 0 223 (194-326) 132 (113-172) <0.001 
Hour 8 245 (209-307) 202 (153-269) 0.073 
Hour 24 418 (352-489) 389 (305-474) 0.264 
Hour 48 629 (516-717) 574 (465-714) 0.577 
Hour 72 694 (612-819) 746 (642-864) 0.411 
PFA-100 collagen/epinephrine closure time, sec (REF 
<180): 
   
Hour 0 98 (85-152) 130 (108-214) 0.090 
Hour 8 107 (84-143) 108 (78-127) 0.768 
Hour 24 102 (86-171) 120 (95-157) 0.715 
Hour 48 111 (86-140) 144 (123-296) 0.029 
Hour 72 103 (92-142) 144 (103-217) 0.222 
PFA-100 collagen/ADP closure time, sec (REF <120):    
Hour 0 64 (53-82) 70 (52-79) 0.955 
Hour 8 66 (56-78) 87 (59-211) 0.039 
Hour 24 83 (67-96) 100 (71-112) 0.122 
Hour 48 99 (77-136) 157 (114-236) 0.005 
Hour 72 100 (81-147) 279 (99-300) 0.018 
Platelet ADP aggregation, ohms (REF 6-24):    
Hour 0 10.8 (7.5-13.0) 7.3 (4.5-8.0) 0.002 
Hour 8 9.5 (7.0-13.0) 9.8 (5.5-12.3) 0.609 
Hour 24 10.5 (7-15) 10.3 (6-12) 0.593 
Hour 48 10.5 (8.5-13) 11 (9.3-13.3) 0.501 
Hour 72 11.3 (9-15) 10.5 (7.5-16.3) 0.524 
Platelet collagen aggregation, ohms (REF 14-28):    
Hour 0 14.5 (11.5-17.5) 11.0 (6.8-12.5) 0.001 
Hour 8 12.5 (10.0-16.0) 11.8 (8.0-14.0) 0.363 
Hour 24 13.8 (11.0-15.5) 15.0 (11.3-16.5) 0.481 
Hour 48 13.5 (11.5-15.5) 13.8 (12.3-16.3) 0.759 
Hour 72 14.3 (11.0-18.0) 13.0 (11.8-17.3) 0.955 
HAS platelet contractile force, kdynes (REF 4.5-9.5):    
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Hour 0 8.4 (6.8-9.6) 5.8 (3.8-8.1) 0.002 
Hour 8 6.7 (5.2-9.3) 6.4 (5.6-7.7) 0.388 
Hour 24 6.9 (5.0-8.6) 8.2 (7.2-11.0) 0.122 
Hour 48 9.1 (5.9-13.1) 9.5 (6.5-11.8) 0.867 
Hour 72 10.2 (7.6-14.4) 8.0 (7.7-13.8) 0.668 
HAS clot elastic modulus, kdynes/cm
2
  (REF 14-35):   
Hour 0 29.2 (22.9-37.0) 23.6 (17.9-30.0) 0.051 
Hour 8 23.6 (18.6-30.9) 20.7 (16.4-26.3) 0.388 
Hour 24 24.7 (17.6-31.9) 26.9 (21.2-40.5) 0.273 
Hour 48 41.8 (17.4-47.3) 26.3 (17.1-42.0) 0.403 
Hour 72 37.8 (21.7-52.0) 21.5 (16.0-56.4) 0.384 
TEG MA, mm (REF 50-70):    
Hour 0 63.0 (58.8-65.1) 54.6 (50.9-59.1) <0.001 
Hour 8 61.7 (58.3-66.0) 62.6 (58.2-64.1) 0.586 
Hour 24 64.0 (61.9-67.1) 64.9 (61.4-66.2) 0.901 
Hour 48 67.3 (65.1-70.4) 65.2 (64.2-69.1) 0.303 
Hour 72 68.9 (66.6-72.0) 69.4 (64.8-71.6) 0.650 
TEG LY30, % (REF <7.5):    
Hour 0 0.2 (0-1.4) 2.3 (0.1-5.8) 0.074 
Hour 8 0.1 (0-0.6) 0 (0-0.3) 0.446 
Hour 24 0.7 (0-1.6) 0.7 (0.1-1.6) 0.836 
Hour 48 1.1 (0.2-2.6) 1.3 (0.2-2.1) 0.980 
Hour 72 0.6 (0-2.1) 0.7 (0.1-1.3) 0.605 
TEG-PM ADP inhibition, %:    
Hour 0 81.4 (61.4-94.7) 94.6 (64.4-99.8) 0.291 
Hour 8 57.4 (38.0-96.4) 67.5 (28.4-96.7) 0.706 
Hour 24 37.9 (30.0-61.5) 27.9 (19.4-84.4) 0.484 
Hour 48 35.7 (19.4-63.8) 26.3 (10.0-54.3) 0.443 
Hour 72 42.2 (27.2-61.0) 44.4 (7.1-61.7) 0.886 
TEG-PM AA inhibition, %:    
Hour 0 40.7 (21.8-62.9) 37.2 (24.7-54.5) 0.706 
Hour 8 36.8 (17.6-86.0) 40.2 (1.2-61.5) 0.641 
Hour 24 23.3 (6.3-62.8) 16.8 (9.4-27.3) 0.511 
Hour 48 24.9 (1.6-59.1) 6.0 (0-24.4) 0.206 
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Hour 72 21.4 (0-55.7) 7.5 (0-28.1) 0.569 
Percent PAC-1-positive:    
Hour 0 3.7 (2.1-12.5) 3.1 (0.5-13.1) 0.417 
Hour 8 10.5 (0.3-35.7) 11.0 (4.7-18.9) 0.980 
Hour 24 12.4 (2.2-25.9) 14.7 (4.7-19.0) 0.979 
Hour 48 18.6 (8.5-30.6) 12.7 (5.0-17.8) 0.341 
Hour 72 14.4 (3.4-28.1) 19.3 (1.8-30.9) 0.716 
Percent CD62P-positive:    
Hour 0 3.2 (1.3-7.9) 2.4 (0.9-2.6) 0.180 
Hour 8 2.8 (0.8-5.1) 2.4 (1.5-3.8) 0.910 
Hour 24 1.6 (0.4-3.8) 1.1 (0.9-2.0) 0.577 
Hour 48 1.6 (0.6-4.8) 0.8 (0.6-2.3) 0.458 
Hour 72 2.0 (0.8-8.5) 2.8 (1.3-3.4) 0.874 
Percent that became CD62P-positive after ADP 
stimulation: 
   
Hour 0 69.6 (59.6-75.8) 65.8 (49.5-75.1) 0.585 
Hour 8 64.9 (57.6-72.6) 64.1 (55.9-67.9) 0.471 
Hour 24 69.6 (55.3-75.1) 60.6 (53.2-67.5) 0.178 
Hour 48 68.2 (58.2-73.1) 58.3 (54.0-69.7) 0.270 
Hour 72 67.6 (55.3-74.0) 66.6 (60.3-73.9) 0.803 
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Figure 1. Platelets showed no difference in activation patterns between the TIC and non-TIC groups. 
Plots show mean ± standard error. (A) CD62P expression in unstimulated patient sample was not 
significantly different between groups at any time point. (B) PAC-1 expression in unstimulated sample 
also showed no significant difference between groups at any time point. (C) Additional CD62P 
expression that is inducible by ex vivo addition of ADP also showed no significant difference between 
groups at any time point. 
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Figure 2. Graphic representation of platelet dysfunction in TIC. Granule secretion in response to agonist 
exposure is preserved in TIC platelets. However, compared to normal platelets, TIC platelets exhibit 
impaired aggregation and contraction. The combination of normal activatability and impaired 
aggregation suggests that platelet dysfunction in TIC likely arises from either intrinsic platelet or integrin 
dysfunction.  
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